The erbium micropeel

A prospective, randomized trial of the effects of two fluence settings on facial photoaging

Brian Somoano, Basil M. Hantash, Edgar F. Fincher, Peggy Wu, Hayes B. Gladstone

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Recent studies have suggested that a series of low-energy, single-pass ablative laser resurfacing micropeels can reduce photoaging with decreased downtime. This randomized, prospective single-blinded trial sought to determine the ideal settings of sequential erbium:yttrium-aluminum-garnet (Er:YAG) laser treatments that maximize efficacy and patient satisfaction. Methods: Forty-six subjects with mild-to-moderate facial dyschromia and rhytides were evenly randomized to two Er:YAG treatment arms. Patients in the lower fluence (LF) (2.5 J/cm2) and higher fluence (HF) (3.8 J/cm2) groups each received three one-pass, full-face treatments one month apart. Patient and investigator assessments of rhytides, dyschromia and global appearance were performed at baseline and at four, eight and 20 weeks using a nominal scale from 1-4. Adverse events and patient satisfaction were also evaluated. Results: Patient scores showed rhytid improvement only with HF treatments. Investigator scores at three months post-treatment showed dyschromia was significantly improved in both study arms, with a 24 and 36 percent reduction for the LF and HF groups, respectively. Global appearance scores improved by 25 and 32 percent, respectively. A trend towards greater post-procedure erythema and time-to-erythema resolution was observed in the HF group. Mild peeling was the most common adverse event. Individuals who underwent LF treatments were more likely to pursue future treatments. Conclusion: Both settings resulted in moderate but significant improvement in dyschromia, although only HF treatment improved rhytides. The decreased downtime of LF treatments made this the preferred choice of patients.

Original languageEnglish (US)
Pages (from-to)179-185
Number of pages7
JournalJournal of Drugs in Dermatology
Volume10
Issue number2
StatePublished - Feb 1 2011
Externally publishedYes

Fingerprint

Erbium
Therapeutics
Erythema
Patient Satisfaction
Arm
Research Personnel
Solid-State Lasers
Lasers

ASJC Scopus subject areas

  • Dermatology

Cite this

The erbium micropeel : A prospective, randomized trial of the effects of two fluence settings on facial photoaging. / Somoano, Brian; Hantash, Basil M.; Fincher, Edgar F.; Wu, Peggy; Gladstone, Hayes B.

In: Journal of Drugs in Dermatology, Vol. 10, No. 2, 01.02.2011, p. 179-185.

Research output: Contribution to journalArticle

Somoano, Brian ; Hantash, Basil M. ; Fincher, Edgar F. ; Wu, Peggy ; Gladstone, Hayes B. / The erbium micropeel : A prospective, randomized trial of the effects of two fluence settings on facial photoaging. In: Journal of Drugs in Dermatology. 2011 ; Vol. 10, No. 2. pp. 179-185.
@article{c4a3a99b66bd45e2a27e6fa3d9a0bae2,
title = "The erbium micropeel: A prospective, randomized trial of the effects of two fluence settings on facial photoaging",
abstract = "Background: Recent studies have suggested that a series of low-energy, single-pass ablative laser resurfacing micropeels can reduce photoaging with decreased downtime. This randomized, prospective single-blinded trial sought to determine the ideal settings of sequential erbium:yttrium-aluminum-garnet (Er:YAG) laser treatments that maximize efficacy and patient satisfaction. Methods: Forty-six subjects with mild-to-moderate facial dyschromia and rhytides were evenly randomized to two Er:YAG treatment arms. Patients in the lower fluence (LF) (2.5 J/cm2) and higher fluence (HF) (3.8 J/cm2) groups each received three one-pass, full-face treatments one month apart. Patient and investigator assessments of rhytides, dyschromia and global appearance were performed at baseline and at four, eight and 20 weeks using a nominal scale from 1-4. Adverse events and patient satisfaction were also evaluated. Results: Patient scores showed rhytid improvement only with HF treatments. Investigator scores at three months post-treatment showed dyschromia was significantly improved in both study arms, with a 24 and 36 percent reduction for the LF and HF groups, respectively. Global appearance scores improved by 25 and 32 percent, respectively. A trend towards greater post-procedure erythema and time-to-erythema resolution was observed in the HF group. Mild peeling was the most common adverse event. Individuals who underwent LF treatments were more likely to pursue future treatments. Conclusion: Both settings resulted in moderate but significant improvement in dyschromia, although only HF treatment improved rhytides. The decreased downtime of LF treatments made this the preferred choice of patients.",
author = "Brian Somoano and Hantash, {Basil M.} and Fincher, {Edgar F.} and Peggy Wu and Gladstone, {Hayes B.}",
year = "2011",
month = "2",
day = "1",
language = "English (US)",
volume = "10",
pages = "179--185",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "2",

}

TY - JOUR

T1 - The erbium micropeel

T2 - A prospective, randomized trial of the effects of two fluence settings on facial photoaging

AU - Somoano, Brian

AU - Hantash, Basil M.

AU - Fincher, Edgar F.

AU - Wu, Peggy

AU - Gladstone, Hayes B.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Background: Recent studies have suggested that a series of low-energy, single-pass ablative laser resurfacing micropeels can reduce photoaging with decreased downtime. This randomized, prospective single-blinded trial sought to determine the ideal settings of sequential erbium:yttrium-aluminum-garnet (Er:YAG) laser treatments that maximize efficacy and patient satisfaction. Methods: Forty-six subjects with mild-to-moderate facial dyschromia and rhytides were evenly randomized to two Er:YAG treatment arms. Patients in the lower fluence (LF) (2.5 J/cm2) and higher fluence (HF) (3.8 J/cm2) groups each received three one-pass, full-face treatments one month apart. Patient and investigator assessments of rhytides, dyschromia and global appearance were performed at baseline and at four, eight and 20 weeks using a nominal scale from 1-4. Adverse events and patient satisfaction were also evaluated. Results: Patient scores showed rhytid improvement only with HF treatments. Investigator scores at three months post-treatment showed dyschromia was significantly improved in both study arms, with a 24 and 36 percent reduction for the LF and HF groups, respectively. Global appearance scores improved by 25 and 32 percent, respectively. A trend towards greater post-procedure erythema and time-to-erythema resolution was observed in the HF group. Mild peeling was the most common adverse event. Individuals who underwent LF treatments were more likely to pursue future treatments. Conclusion: Both settings resulted in moderate but significant improvement in dyschromia, although only HF treatment improved rhytides. The decreased downtime of LF treatments made this the preferred choice of patients.

AB - Background: Recent studies have suggested that a series of low-energy, single-pass ablative laser resurfacing micropeels can reduce photoaging with decreased downtime. This randomized, prospective single-blinded trial sought to determine the ideal settings of sequential erbium:yttrium-aluminum-garnet (Er:YAG) laser treatments that maximize efficacy and patient satisfaction. Methods: Forty-six subjects with mild-to-moderate facial dyschromia and rhytides were evenly randomized to two Er:YAG treatment arms. Patients in the lower fluence (LF) (2.5 J/cm2) and higher fluence (HF) (3.8 J/cm2) groups each received three one-pass, full-face treatments one month apart. Patient and investigator assessments of rhytides, dyschromia and global appearance were performed at baseline and at four, eight and 20 weeks using a nominal scale from 1-4. Adverse events and patient satisfaction were also evaluated. Results: Patient scores showed rhytid improvement only with HF treatments. Investigator scores at three months post-treatment showed dyschromia was significantly improved in both study arms, with a 24 and 36 percent reduction for the LF and HF groups, respectively. Global appearance scores improved by 25 and 32 percent, respectively. A trend towards greater post-procedure erythema and time-to-erythema resolution was observed in the HF group. Mild peeling was the most common adverse event. Individuals who underwent LF treatments were more likely to pursue future treatments. Conclusion: Both settings resulted in moderate but significant improvement in dyschromia, although only HF treatment improved rhytides. The decreased downtime of LF treatments made this the preferred choice of patients.

UR - http://www.scopus.com/inward/record.url?scp=80052062561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052062561&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 179

EP - 185

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 2

ER -